Olezarsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)
Part of paid clinical trials in Carlsbad, California.
- Sponsor
- Ionis Pharmaceuticals, Inc.
- Study ID
- NCT06360237
- Status
- Approved For Marketing
Conditions
- Familial Chylomicronemia Syndrome
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Olezarsen — DRUGOlezarsen 80 mg administered once monthly by subcutaneous (SC) injections in the abdomen, thigh, or upper arm.
Study Details
The purpose of the Expanded Access Program is to provide pre-approval access of olezarsen to eligible patients with Familial Chylomicronemia Syndrome (FCS).
Key Dates
- Status verified
- Dec 2024
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Expanded Access Site | Carlsbad | California | 92010 | - |
Find similar trials in Carlsbad, CA
By research site